TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 6.2% of TScan Therapeutics shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares TScan Therapeutics and Korro Bio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TScan Therapeutics | $10.32 million | 2.10 | -$129.77 million | ($0.91) | -0.35 |
| Korro Bio | $2.38 million | 59.60 | -$117.26 million | ($10.00) | -0.96 |
Korro Bio has lower revenue, but higher earnings than TScan Therapeutics. Korro Bio is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and target prices for TScan Therapeutics and Korro Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
TScan Therapeutics currently has a consensus target price of $2.67, indicating a potential upside of 732.03%. Korro Bio has a consensus target price of $16.71, indicating a potential upside of 73.38%. Given TScan Therapeutics’ higher probable upside, equities research analysts clearly believe TScan Therapeutics is more favorable than Korro Bio.
Risk and Volatility
TScan Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3.14, suggesting that its stock price is 214% more volatile than the S&P 500.
Profitability
This table compares TScan Therapeutics and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
| Korro Bio | N/A | -114.26% | -68.57% |
Summary
TScan Therapeutics beats Korro Bio on 8 of the 15 factors compared between the two stocks.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
